Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to agalsidase beta versus continue migalastat in classic Fabry disease
2019-000065-20Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Fabry disease (FD) comparing Switch to Fabrazyme with Continue Galafold (2 arms). Primary endpoint: Change from baseline in plasma globotriaosylsphingosine level. Started Oct 2019; status: terminated.
02
Drugs
agalsidase betamigalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2019-000065-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000065-20.